The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

In the randomized dose-expansion phase of a Phase 1 study (NCT03460977), the combination of mevrometostat (1250 mg twice daily on an empty stomach) and enzalutamide (160 mg once daily) demonstrated ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...